The board of directors of SSY Group Limited announced that the Group's Betahistine Mesilate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Betahistine Mesilate is mainly used in the treatment of dizziness and lightheadedness associated with Meniere's disease, Meniere's syndrome and vertigo. In addition, the Board is also pleased to announce that the Group's Epinephrine has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

Epinephrine is mainly used in the rescue of cardiac arrest and anaphylaxis, can be used in the treatment of other allergic diseases (such as bronchial asthma and urticaria), and can also be used in combination with local anesthetic to facilitate local hemostasis and help prolong drug effect.